Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: Health Care Equipment
- Symbol: NYSE:BSX
- CUSIP: 10113710
- Web: www.bostonscientific.com
Capitalization:- Market Cap: $36.55346 billion
- Outstanding Shares: 1,372,127,000
Average Prices:- 50 Day Moving Avg: $27.16
- 200 Day Moving Avg: $26.15
- 52 Week Range: $19.67 - $28.51
P/E:- Trailing P/E Ratio: 48.10
- Foreward P/E Ratio: 19.35
- P/E Growth: 1.94
Sales & Book Value:- Annual Revenue: $8.71 billion
- Price / Sales: 4.24
- Book Value: $5.28 per share
- Price / Book: 5.09
Profitability:- EBIDTA: $2.31 billion
- Net Margins: 9.04%
- Return on Equity: 23.62%
- Return on Assets: 9.01%
Debt:- Debt-to-Equity Ratio: 0.67%
- Current Ratio: 0.75%
- Quick Ratio: 0.51%
Misc:- Average Volume: 6.10 million shs.
- Beta: 1.09
- Short Ratio: 1.48
Frequently Asked Questions for Boston Scientific Corporation (NYSE:BSX)
What is Boston Scientific Corporation's stock symbol?
Boston Scientific Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."
How were Boston Scientific Corporation's earnings last quarter?
Boston Scientific Corporation (NYSE:BSX) issued its quarterly earnings results on Thursday, July, 27th. The company reported $0.32 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.31 by $0.01. The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The company's revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.27 earnings per share. View Boston Scientific Corporation's Earnings History.
When will Boston Scientific Corporation make its next earnings announcement?
What guidance has Boston Scientific Corporation issued on next quarter's earnings?
Boston Scientific Corporation issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $1.23-1.27 for the period, compared to the Thomson Reuters consensus estimate of $1.25. The company issued revenue guidance of $8.89-8.99 billion, compared to the consensus revenue estimate of $8.87 billion.Boston Scientific Corporation also updated its Q3 guidance to $0.29-0.31 EPS.
Where is Boston Scientific Corporation's stock going? Where will Boston Scientific Corporation's stock price be in 2017?
17 brokerages have issued twelve-month target prices for Boston Scientific Corporation's stock. Their predictions range from $28.00 to $33.00. On average, they anticipate Boston Scientific Corporation's share price to reach $30.39 in the next year. View Analyst Ratings for Boston Scientific Corporation.
What are analysts saying about Boston Scientific Corporation stock?
Here are some recent quotes from research analysts about Boston Scientific Corporation stock:
- 1. According to Zacks Investment Research, "Boston Scientific posted a better-than-expected second quarter, with earnings and revenues both remaining ahead of the Zacks Consensus Estimate. On a positive note, the company is leaving no stone unturned to strengthen its core businesses and invest more in global markets. Among the recent developments, worth mentioning is the company’s acquisition of Symetis, in a bid to fortify its structural heart business in Europe. We are also encouraged with the company gaining a number of product approvals both in the domestic and overseas markets. Notably, the company received an FDA approval for the RESONATE family of ICD and CRT-D systems. Yet, the recent recall of its Lotus range of heart devices hampered sales in the quarter. Also the unimpressive defibrillator performance within the core CRM continues to remain a drag. We are still concerned about the foreign exchange headwind. In general, over the past three months, Boston Scientific is trading below the broader industry." (7/31/2017)
- 2. Needham & Company LLC analysts commented, "BSX beat consensus 1Q17 revenue but missed consensus EPS due to expense associated with the Lotus withdrawal. Management raised its revenue guidance but maintained its EPS guidance for 2017. BSX’s organic revenue growth slowed slightly to 9% in 1Q17 from 10% in 4Q16 despite facing a more difficult comp. MedSurg growth accelerated and offset slower Cardiovascular growth as BSX lapped the US Synergy launch. Margins were below expectations with BSX’s gross margin down 170 bps Y/Y and operating margin down 210 bps Y/Y but this was mostly due to the impact of the Lotus withdrawal." (4/27/2017)
- 3. Northland Securities analysts commented, "The implications for Edwards now are a longer runway without BSX truly being on the market, potential questions arising about product design / reliability of the Lotus Valve. More importantly, Edwards now has a chance to pick up incremental share in Europe. We remain strong buyers of EW." (2/23/2017)
Who are some of Boston Scientific Corporation's key competitors?
Some companies that are related to Boston Scientific Corporation include Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), Intuitive Surgical (ISRG), Koninklijke Philips N.V. (PHG), Illumina (ILMN), Edwards Lifesciences Corporation (EW), Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), Hologic (HOLX), ResMed (RMD), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Accelerate Diagnostics (AXDX) and Natus Medical Incorporated (BABY).
Who are Boston Scientific Corporation's key executives?
Boston Scientific Corporation's management team includes the folowing people:
- Michael F. Mahoney, Chairman of the Board, President, Chief Executive Officer
- Daniel J. Brennan, Chief Financial Officer, Executive Vice President
- Timothy A. Pratt, Chief Administrative Officer, Executive Vice President, General Counsel, Secretary
- Supratim Bose, Executive Vice President; President, Asia-Pacific, Middle East and Africa
- Keith D. Dawkins M.D., Global Chief Medical Officer, Executive Vice President
- Joseph M. Fitzgerald, Executive Vice President; President - Rhythm Management
- Edward F. Mackey, Executive Vice President - Operations
- Ian T. Meredith AM, Executive Vice President, Global Chief Medical Officer
- Michael P. Phalen, Executive Vice President; President - MedSurg
- Wendy Carruthers, Senior Vice President - Human Resources
Who owns Boston Scientific Corporation stock?
Boston Scientific Corporation's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (12.72%), Capital World Investors (7.43%), BlackRock Inc. (7.31%), Vanguard Group Inc. (6.83%), State Street Corp (4.17%) and Janus Henderson Group PLC (2.83%). Company insiders that own Boston Scientific Corporation stock include Charles J Dockendorff, Daniel J Brennan, David A Pierce, Ernest Mario, Jeffrey B Mirviss, John Bradley Sorenson, John E Abele, Joseph Michael Fitzgerald, Karen Prange, Keith D Dawkins, Kevin J Ballinger, Michael F Mahoney, Michael P Phalen, Timothy A Pratt and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific Corporation.
Who sold Boston Scientific Corporation stock? Who is selling Boston Scientific Corporation stock?
Boston Scientific Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Artisan Partners Limited Partnership, Standard Life Investments LTD, Marshall Wace North America L.P., Arrowstreet Capital Limited Partnership, Gotham Asset Management LLC, Bollard Group LLC and BNP Paribas Arbitrage SA. Company insiders that have sold Boston Scientific Corporation stock in the last year include Daniel J Brennan, David A Pierce, John Bradley Sorenson, Keith D Dawkins, Kevin J Ballinger, Michael P Phalen, Timothy A Pratt and Wendy Carruthers. View Insider Buying and Selling for Boston Scientific Corporation.
Who bought Boston Scientific Corporation stock? Who is buying Boston Scientific Corporation stock?
Boston Scientific Corporation's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Jennison Associates LLC, BlackRock Inc., Los Angeles Capital Management & Equity Research Inc., Vanguard Group Inc., Winslow Capital Management LLC, Capital World Investors and Eaton Vance Management. Company insiders that have bought Boston Scientific Corporation stock in the last two years include Charles J Dockendorff and John E Abele. View Insider Buying and Selling for Boston Scientific Corporation.
How do I buy Boston Scientific Corporation stock?
Shares of Boston Scientific Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Boston Scientific Corporation's stock price today?
One share of Boston Scientific Corporation stock can currently be purchased for approximately $26.89.
MarketBeat Community Rating for Boston Scientific Corporation (NYSE BSX)MarketBeat's community ratings are surveys of what our community members think about Boston Scientific Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Boston Scientific Corporation (NYSE:BSX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 13 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.76) |
| Consensus Price Target: | $30.39 (13.03% upside) |
Analysts' Ratings History for Boston Scientific Corporation (NYSE:BSX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/9/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Hold | | Medium |  |
| 7/30/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $32.00 | Medium | |
| 7/28/2017 | Cowen and Company | Reiterated Rating | Buy | $31.00 -> $32.00 | Low | |
| 7/12/2017 | Royal Bank Of Canada | Reiterated Rating | Buy | $31.00 | Low | |
| 6/28/2017 | J P Morgan Chase & Co | Reiterated Rating | Overweight | $27.00 -> $31.00 | Low | |
| 6/28/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $28.00 | Low | |
| 6/28/2017 | Barclays PLC | Boost Price Target | Overweight -> Overweight | $30.00 -> $31.00 | Low | |
| 6/22/2017 | Needham & Company LLC | Boost Price Target | Buy | $30.00 -> $32.00 | Low | |
| 6/21/2017 | BMO Capital Markets | Reiterated Rating | Buy | $30.00 | Low | |
| 6/16/2017 | Wells Fargo & Company | Reiterated Rating | Outperform | $29.50 -> $31.00 | Low | |
| 5/16/2017 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral -> Neutral | $28.00 | Low | |
| 4/28/2017 | Evercore ISI | Boost Price Target | Outperform | $26.50 -> $28.50 | Low | |
| 4/12/2017 | Guggenheim | Reiterated Rating | Buy | | Low | |
| 2/23/2017 | Northland Securities | Reiterated Rating | Positive | | N/A | |
| 2/5/2017 | BTIG Research | Reiterated Rating | Hold | | N/A | |
| 10/6/2016 | Citigroup Inc. | Boost Price Target | Buy | $28.00 -> $29.00 | N/A | |
| 9/1/2016 | Argus | Upgrade | Hold -> Buy | $23.82 -> $33.00 | N/A | |
| 7/29/2016 | Credit Suisse Group | Reiterated Rating | Buy | | N/A | |
| 7/29/2016 | Leerink Swann | Reiterated Rating | Buy | | N/A | |
| 7/29/2016 | Wedbush | Boost Price Target | Neutral | $23.00 -> $25.00 | N/A | |
| 7/28/2016 | Benchmark Co. | Boost Price Target | Buy | $25.00 -> $31.00 | N/A | |
| 6/21/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $26.00 | N/A | |
| 3/27/2016 | Morgan Stanley | Reiterated Rating | Overweight | $22.00 | N/A | |
| 3/25/2016 | Bank of America Corporation | Reiterated Rating | Buy | $23.00 | N/A | |
| 3/18/2016 | Longbow Research | Initiated Coverage | Buy | | N/A | |
| 3/17/2016 | Nomura | Initiated Coverage | Buy | $22.00 | N/A | |
| 3/12/2016 | Deutsche Bank AG | Reiterated Rating | Hold | | N/A | |
| 2/25/2016 | SunTrust Banks, Inc. | Initiated Coverage | Buy | $21.00 | N/A | |
| 1/4/2016 | Sterne Agee CRT | Boost Price Target | Buy | $21.00 -> $22.50 | N/A | |
(Data available from 8/19/2015 forward)
Earnings History for Boston Scientific Corporation (NYSE:BSX)Earnings History by Quarter for Boston Scientific Corporation (NYSE BSX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/24/2017 | | $0.31 | | | | | N/A | |
| 7/27/2017 | Q2 2017 | $0.31 | $0.32 | $2.21 billion | $2.26 billion | View | N/A | |
| 4/27/2017 | Q1 2017 | $0.30 | $0.29 | $2.08 billion | $2.16 billion | View | N/A | |
| 2/2/2017 | Q416 | $0.29 | $0.30 | $2.16 billion | $2.19 billion | View | Listen | |
| 10/26/2016 | Q316 | $0.27 | $0.27 | $2.07 billion | $2.11 billion | View | Listen | |
| 7/28/2016 | Q216 | $0.27 | $0.27 | $2.05 billion | $2.13 billion | View | Listen | |
| 4/27/2016 | Q116 | $0.24 | $0.28 | $1.91 billion | $1.96 billion | View | Listen | |
| 2/4/2016 | Q415 | $0.25 | $0.26 | $2.00 billion | $1.98 billion | View | Listen | |
| 10/28/2015 | Q315 | $0.23 | $0.24 | $1.86 billion | $1.89 billion | View | Listen | |
| 7/23/2015 | Q215 | $0.21 | $0.22 | $1.83 billion | $1.84 billion | View | Listen | |
| 4/28/2015 | Q115 | $0.21 | $0.21 | $1.78 billion | $1.77 billion | View | Listen | |
| 2/4/2015 | Q414 | $0.21 | $0.22 | $1.91 billion | $1.89 billion | View | Listen | |
| 10/22/2014 | Q314 | $0.20 | $0.20 | $1.82 billion | $1.85 billion | View | Listen | |
| 7/24/2014 | Q214 | $0.20 | $0.21 | $1.87 billion | $1.87 billion | View | Listen | |
| 4/29/2014 | Q114 | $0.18 | $0.20 | $1.80 billion | $1.77 billion | View | Listen | |
| 2/4/2014 | Q4 | $0.13 | $0.21 | $1.83 billion | $1.84 billion | View | Listen | |
| 10/24/2013 | Q313 | $0.09 | $0.17 | $1.73 billion | $1.74 billion | View | Listen | |
| 7/25/2013 | Q2 2013 | $0.10 | $0.18 | $1.78 billion | $1.81 billion | View | Listen | |
| 4/25/2013 | Q1 2013 | $0.09 | $0.16 | $1.79 billion | $1.76 billion | View | Listen | |
| 1/29/2013 | Q4 2012 | $0.11 | $0.18 | $1.76 billion | $1.82 billion | View | Listen | |
| 10/18/2012 | | $0.11 | ($0.52) | | | View | N/A | |
| 7/26/2012 | | $0.08 | $0.17 | | | View | N/A | |
| 4/19/2012 | | $0.13 | $0.15 | | | View | N/A | |
| 2/2/2012 | | $0.08 | $0.07 | | | View | N/A | |
| 10/20/2011 | | $0.09 | $0.15 | | | View | N/A | |
| 7/28/2011 | | $0.08 | $0.17 | | | View | N/A | |
| 4/20/2011 | | $0.04 | $0.01 | | | View | N/A | |
| 2/1/2011 | | $0.09 | $0.15 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Boston Scientific Corporation (NYSE:BSX)2017 EPS Consensus Estimate: $1.25
2018 EPS Consensus Estimate: $1.41
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 5 | $0.29 | $0.31 | $0.30 |
| Q2 2017 | 5 | $0.31 | $0.31 | $0.31 |
| Q3 2017 | 6 | $0.30 | $0.32 | $0.31 |
| Q4 2017 | 5 | $0.32 | $0.35 | $0.33 |
| Q1 2018 | 2 | $0.29 | $0.30 | $0.30 |
| Q2 2018 | 2 | $0.35 | $0.36 | $0.36 |
| Q3 2018 | 3 | $0.35 | $0.37 | $0.36 |
| Q4 2018 | 2 | $0.39 | $0.40 | $0.40 |
(Data provided by Zacks Investment Research)
Dividend History for Boston Scientific Corporation (NYSE:BSX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Boston Scientific Corporation (NYSE:BSX)Insider Ownership Percentage: 0.74%
Institutional Ownership Percentage: 91.62%
Insider Trades by Quarter for Boston Scientific Corporation (NYSE:BSX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/3/2017 | Wendy Carruthers | SVP | Sell | 12,433 | $26.75 | $332,582.75 | |
| 8/2/2017 | John Bradley Sorenson | SVP | Sell | 7,900 | $26.37 | $208,323.00 | |
| 8/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $26.67 | $266,700.00 | |
| 7/31/2017 | John Bradley Sorenson | SVP | Sell | 2,100 | $27.15 | $57,015.00 | |
| 7/31/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $27.13 | $420,515.00 | |
| 7/11/2017 | Daniel J Brennan | CFO | Sell | 92,158 | $27.48 | $2,532,501.84 | |
| 7/3/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $27.87 | $278,700.00 | |
| 6/29/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $28.02 | $434,310.00 | |
| 6/9/2017 | David A Pierce | SVP | Sell | 13,562 | $28.00 | $379,736.00 | |
| 6/2/2017 | David A Pierce | SVP | Sell | 2,972 | $27.70 | $82,324.40 | |
| 6/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $27.13 | $271,300.00 | |
| 5/30/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $27.25 | $422,375.00 | |
| 5/17/2017 | Kevin J. Ballinger | EVP | Sell | 28,864 | $26.14 | $754,504.96 | |
| 5/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $26.37 | $263,700.00 | |
| 4/26/2017 | David A Pierce | SVP | Sell | 10,250 | $26.00 | $266,500.00 | |
| 4/26/2017 | Michael P. Phalen | EVP | Sell | 34,773 | $26.00 | $904,098.00 | |
| 4/10/2017 | John Bradley Sorenson | SVP | Sell | 2,950 | $24.66 | $72,747.00 | |
| 4/3/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $24.87 | $248,700.00 | |
| 3/29/2017 | Michael P. Phalen | EVP | Sell | 79,045 | $24.55 | $1,940,554.75 | |
| 3/3/2017 | David A Pierce | SVP | Sell | 25,012 | $25.01 | $625,550.12 | |
| 3/3/2017 | Timothy A Pratt | EVP | Sell | 23,540 | $25.01 | $588,735.40 | |
| 2/27/2017 | David A Pierce | SVP | Sell | 3,417 | $24.84 | $84,878.28 | |
| 2/27/2017 | Timothy A Pratt | EVP | Sell | 4,832 | $24.84 | $120,026.88 | |
| 2/7/2017 | Keith D Dawkins | EVP | Sell | 80,783 | $25.21 | $2,036,539.43 | |
| 1/9/2017 | David A Pierce | SVP | Sell | 10,232 | $22.24 | $227,559.68 | |
| 1/9/2017 | Timothy A Pratt | EVP | Sell | 6,195 | $22.24 | $137,776.80 | |
| 12/1/2016 | Timothy A Pratt | EVP | Sell | 26,726 | $20.48 | $547,348.48 | |
| 8/11/2016 | John Bradley Sorenson | SVP | Sell | 2,500 | $23.90 | $59,750.00 | |
| 8/1/2016 | Michael F Mahoney | CEO | Sell | 44,400 | $24.44 | $1,085,136.00 | |
| 8/1/2016 | Timothy A Pratt | EVP | Sell | 24,000 | $24.46 | $587,040.00 | |
| 7/20/2016 | David A Pierce | SVP | Sell | 2,480 | $24.03 | $59,594.40 | |
| 7/20/2016 | Michael P. Phalen | EVP | Sell | 35,000 | $24.03 | $841,050.00 | |
| 6/1/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $22.69 | $2,269,000.00 | |
| 6/1/2016 | Timothy A Pratt | EVP | Sell | 24,229 | $22.66 | $549,029.14 | |
| 5/11/2016 | John Bradley Sorenson | SVP | Sell | 2,800 | $22.15 | $62,020.00 | |
| 5/10/2016 | Keith D Dawkins | EVP | Sell | 80,000 | $22.15 | $1,772,000.00 | |
| 5/6/2016 | Jeffrey B Mirviss | SVP | Sell | 24,659 | $21.94 | $541,018.46 | |
| 5/3/2016 | Joseph Michael Fitzgerald | EVP | Sell | 79,960 | $21.81 | $1,743,927.60 | |
| 5/2/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $22.12 | $2,212,000.00 | |
| 5/2/2016 | Timothy A Pratt | EVP | Sell | 24,000 | $21.93 | $526,320.00 | |
| 4/27/2016 | Kevin J Ballinger | SVP | Sell | 111,807 | $21.62 | $2,417,267.34 | |
| 4/27/2016 | Timothy A Pratt | EVP | Sell | 39,927 | $21.40 | $854,437.80 | |
| 4/4/2016 | Jeffrey B Mirviss | SVP | Sell | 18,422 | $19.00 | $350,018.00 | |
| 4/1/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $18.90 | $1,890,000.00 | |
| 4/1/2016 | Timothy A Pratt | EVP | Sell | 24,000 | $18.73 | $449,520.00 | |
| 3/11/2016 | Kevin J Ballinger | SVP | Sell | 16,705 | $18.00 | $300,690.00 | |
| 3/8/2016 | Karen Prange | SVP | Sell | 14,747 | $17.27 | $254,680.69 | |
| 3/2/2016 | Michael P. Phalen | EVP | Sell | 10,665 | $17.17 | $183,118.05 | |
| 3/1/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $16.96 | $1,696,000.00 | |
| 3/1/2016 | Timothy A Pratt | EVP | Sell | 15,068 | $16.97 | $255,703.96 | |
| 2/29/2016 | Kevin J. Ballinger | SVP | Sell | 2,114 | $17.17 | $36,297.38 | |
| 2/29/2016 | Michael P. Phalen | EVP | Sell | 1,819 | $17.19 | $31,268.61 | |
| 2/25/2016 | Daniel J Brennan | CFO | Sell | 103,211 | $17.22 | $1,777,293.42 | |
| 2/25/2016 | Kevin J. Ballinger | SVP | Sell | 1,903 | $17.48 | $33,264.44 | |
| 2/25/2016 | Michael P. Phalen | EVP | Sell | 34,106 | $17.28 | $589,351.68 | |
| 2/17/2016 | Kevin J. Ballinger | SVP | Sell | 7,616 | $17.37 | $132,289.92 | |
| 2/12/2016 | Charles J Dockendorff | Director | Buy | 30,000 | $16.49 | $494,700.00 | |
| 2/8/2016 | Karen Prange | SVP | Sell | 6,216 | $16.05 | $99,766.80 | |
| 1/8/2016 | Timothy A Pratt | EVP | Sell | 7,160 | $17.67 | $126,517.20 | |
| 1/7/2016 | Kevin J Ballinger | SVP | Sell | 19,059 | $17.73 | $337,916.07 | |
| 1/5/2016 | Jeffrey B Mirviss | SVP | Sell | 9,953 | $18.00 | $179,154.00 | |
| 12/1/2015 | Timothy A. Pratt | EVP | Sell | 24,000 | $18.43 | $442,320.00 | |
| 11/16/2015 | Ernest Mario | Director | Sell | 125,000 | $17.63 | $2,203,750.00 | |
| 11/9/2015 | John Bradley Sorenson | SVP | Sell | 4,469 | $18.68 | $83,480.92 | |
| 11/9/2015 | Joseph Michael Fitzgerald | EVP | Sell | 26,220 | $18.58 | $487,167.60 | |
| 11/5/2015 | Timothy A Pratt | EVP | Sell | 19,598 | $19.00 | $372,362.00 | |
| 10/28/2015 | Jeffrey B Mirviss | SVP | Sell | 9,492 | $18.00 | $170,856.00 | |
| 10/28/2015 | Timothy A Pratt | EVP | Sell | 3,500 | $18.00 | $63,000.00 | |
| 10/5/2015 | Timothy A Pratt | EVP | Sell | 3,500 | $17.34 | $60,690.00 | |
| 10/1/2015 | Timothy A. Pratt | EVP | Sell | 17,000 | $16.33 | $277,610.00 | |
| 8/21/2015 | John E Abele | Director | Buy | 200,000 | $16.77 | $3,354,000.00 | |
| 8/19/2015 | John E Abele | Director | Buy | 200,000 | $17.48 | $3,496,000.00 | |
| 8/17/2015 | John E Abele | Director | Buy | 100,000 | $17.50 | $1,750,000.00 | |
| 7/7/2015 | Karen Prange | SVP | Sell | 17,456 | $17.66 | $308,272.96 | |
| 5/29/2015 | Maulik Nanavaty | SVP | Sell | 71,558 | $18.52 | $1,325,254.16 | |
| 5/28/2015 | Wendy Carruthers | SVP | Sell | 42,281 | $17.91 | $757,252.71 | |
| 5/18/2015 | Ernest Mario | Director | Sell | 50,000 | $18.09 | $904,500.00 | |
| 5/14/2015 | John E Sununu | Director | Sell | 10,000 | $17.87 | $178,700.00 | |
| 5/11/2015 | John Bradley Sorenson | SVP | Sell | 8,735 | $17.49 | $152,775.15 | |
| 3/20/2015 | David A Pierce | SVP | Sell | 18,050 | $18.00 | $324,900.00 | |
| 3/20/2015 | Michael P Phalen | EVP | Sell | 46,085 | $17.94 | $826,764.90 | |
| 3/16/2015 | Michael P Phalen | EVP | Sell | 30,022 | $17.18 | $515,777.96 | |
| 3/13/2015 | John Bradley Sorenson | SVP | Sell | 3,830 | $16.84 | $64,497.20 | |
| 3/9/2015 | David A Pierce | SVP | Sell | 2,561 | $16.54 | $42,358.94 | |
| 3/3/2015 | David A Pierce | SVP | Sell | 8,983 | $16.79 | $150,824.57 | |
| 3/3/2015 | Michael P Phalen | EVP | Sell | 12,768 | $16.79 | $214,374.72 | |
| 2/27/2015 | David A Pierce | SVP | Sell | 19,046 | $16.80 | $319,972.80 | |
| 2/27/2015 | Michael P Phalen | EVP | Sell | 1,819 | $16.80 | $30,559.20 | |
| 2/19/2015 | David A Pierce | SVP | Sell | 11,958 | $16.46 | $196,828.68 | |
| 2/19/2015 | Michael P Phalen | EVP | Sell | 13,188 | $16.44 | $216,810.72 | |
| 2/10/2015 | Joseph Michael Fitzgerald | EVP | Sell | 61,208 | $14.66 | $897,309.28 | |
| 2/9/2015 | David A Pierce | SVP | Sell | 5,000 | $14.66 | $73,300.00 | |
| 2/6/2015 | Kevin J Ballinger | SVP | Sell | 21,408 | $15.06 | $322,404.48 | |
| 1/20/2015 | Michael P Phalen | EVP | Sell | 10,000 | $14.54 | $145,400.00 | |
| 1/8/2015 | David A Pierce | SVP | Sell | 18,612 | $14.31 | $266,337.72 | |
| 1/8/2015 | Michael P Phalen | EVP | Sell | 27,589 | $14.31 | $394,798.59 | |
| 1/5/2015 | Michael P Phalen | EVP | Sell | 10,000 | $13.75 | $137,500.00 | |
| 12/10/2014 | Karen Prange | SVP | Sell | 19,753 | $12.64 | $249,677.92 | |
| 12/8/2014 | David A Pierce | SVP | Sell | 5,000 | $12.90 | $64,500.00 | |
| 12/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.96 | $129,600.00 | |
| 11/28/2014 | Michael F Mahoney | CEO | Buy | 11,700 | $12.89 | $150,813.00 | |
| 11/10/2014 | Edward J Ludwig | Director | Buy | 10,000 | $13.38 | $133,800.00 | |
| 11/5/2014 | John E Sununu | Director | Sell | 8,997 | $13.38 | $120,379.86 | |
| 11/3/2014 | Ernest Mario | Director | Sell | 10,000 | $13.30 | $133,000.00 | |
| 10/8/2014 | Ernest Mario | Director | Sell | 10,000 | $12.06 | $120,600.00 | |
| 9/2/2014 | Ernest Mario | Director | Sell | 10,000 | $12.60 | $126,000.00 | |
| 8/15/2014 | Michael P Phalen | EVP | Sell | 11,471 | $12.58 | $144,305.18 | |
| 8/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.58 | $125,800.00 | |
| 7/30/2014 | David A Pierce | SVP | Sell | 157 | $12.97 | $2,036.29 | |
| 7/15/2014 | Michael P Phalen | EVP | Sell | 67,500 | $13.04 | $880,200.00 | |
| 7/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.95 | $129,500.00 | |
| 6/16/2014 | Michael P Phalen | EVP | Sell | 13,500 | $13.02 | $175,770.00 | |
| 6/2/2014 | Ernest Mario | Director | Sell | 10,000 | $12.88 | $128,800.00 | |
| 5/15/2014 | Michael Phalen | EVP | Sell | 13,500 | $12.76 | $172,260.00 | |
| 5/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.58 | $125,800.00 | |
| 4/15/2014 | Michael Phalen | EVP | Sell | 13,500 | $13.25 | $178,875.00 | |
| 4/1/2014 | Ernest Mario | Director | Sell | 10,000 | $13.55 | $135,500.00 | |
| 3/17/2014 | Michael Phalen | EVP | Sell | 13,500 | $13.05 | $176,175.00 | |
| 3/6/2014 | David Pierce | SVP | Sell | 5,316 | $13.44 | $71,447.04 | |
| 3/6/2014 | Michael Phalen | EVP | Sell | 7,281 | $13.44 | $97,856.64 | |
| 2/27/2014 | David Pierce | SVP | Sell | 2,057 | $13.29 | $27,337.53 | |
| 2/27/2014 | Michael Phalen | EVP | Sell | 3,166 | $13.29 | $42,076.14 | |
| 2/21/2014 | David Pierce | SVP | Sell | 3,199 | $13.22 | $42,290.78 | |
| 2/21/2014 | Michael Phalen | EVP | Sell | 3,222 | $13.22 | $42,594.84 | |
| 2/18/2014 | Michael Phalen | EVP | Sell | 13,500 | $13.30 | $179,550.00 | |
| 2/13/2014 | Kristina Johnson | Director | Sell | 18,000 | $13.01 | $234,180.00 | |
| 2/6/2014 | Ernest Mario | Director | Sell | 17,104 | $12.80 | $218,931.20 | |
| 2/3/2014 | Ernest Mario | Director | Sell | 10,000 | $13.19 | $131,900.00 | |
| 1/6/2014 | Ernest Mario | Director | Sell | 10,000 | $12.50 | $125,000.00 | |
| 12/26/2013 | Ernest Mario | Director | Sell | 10,000 | $12.06 | $120,600.00 | |
| 11/26/2013 | Jeffrey Capello | CFO | Sell | 85,106 | $11.82 | $1,005,952.92 | |
| 11/11/2013 | Jeffrey Mirviss | SVP | Sell | 26,000 | $11.91 | $309,660.00 | |
| 8/29/2013 | Jeffrey Capello | CFO | Sell | 525,000 | $10.68 | $5,607,000.00 | |
| 8/16/2013 | Joseph Michael Fitzgerald | SVP | Sell | 9,202 | $11.02 | $101,406.04 | |
| 8/14/2013 | Kevin Ballinger | SVP | Sell | 38,171 | $11.28 | $430,568.88 | |
| 5/31/2013 | Jeffrey B Mirviss | SVP | Sell | 10,941 | $9.37 | $102,517.17 | |
| 5/30/2013 | Wendy Carruthers | SVP | Sell | 25,001 | $9.16 | $229,009.16 | |
| 5/29/2013 | Nelda J Connors | Director | Sell | 24,116 | $9.17 | $221,143.72 | |
| 5/6/2013 | Ernest Mario | Director | Buy | 30,000 | $7.76 | $232,800.00 | |
| 11/13/2012 | Nj Nicholas Jr | Director | Buy | 20,000 | $5.28 | $105,600.00 | |
| 11/9/2012 | Nj Nicholas Jr | Director | Buy | 25,000 | $5.17 | $129,250.00 | |
| 8/6/2012 | Ernest Mario | Director | Buy | 32,000 | $5.29 | $169,280.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Boston Scientific Corporation (NYSE:BSX)
Latest Headlines for Boston Scientific Corporation (NYSE:BSX)
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Brokerages Expect Boston Scientific Corporation (BSX) Will Post Quarterly Sales of $2.20 Billion
www.americanbankingnews.com - August 15 at 1:40 PM |
 | Health care divide leaves tax on path to reinstatement
marketbeat.com - August 13 at 11:01 AM |
| Brokerages Expect Boston Scientific Corporation (BSX) to Announce $0.31 EPS
www.americanbankingnews.com - August 13 at 4:14 AM |
 | IHS Markit Score Update: Drop in demand for ETFs holding Boston Scientific Corp is a negative sign for its shares
finance.yahoo.com - August 11 at 4:02 AM |
| See what the IHS Markit Score report has to say about Boston Scientific Corp.
finance.yahoo.com - August 10 at 2:58 AM |
 | Boston Scientific Corp (BSX) Presents at Canaccord Genuity Growth Broker Conference (Transcript) - Seeking Alpha
seekingalpha.com - August 9 at 9:58 PM |
| Boston Scientific Corporation (NYSE:BSX) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - August 9 at 6:46 PM |
| Boston Scientific Corp. – Value Analysis (NYSE:BSX) : August 8, 2017
finance.yahoo.com - August 8 at 9:36 PM |
 | BRIEF-Boston Scientific Corp says entered into a $2.25 bln senior unsecured credit facility- SEC Filing
www.reuters.com - August 7 at 5:18 PM |
| BRIEF-Boston Scientific Corp says entered into a $2.25 bln senior unsecured credit facility- SEC Filing
www.reuters.com - August 7 at 5:18 PM |
 | Notice of REVA Medical Briefing Call
feeds.benzinga.com - August 7 at 1:21 PM |
| Insider Selling: Boston Scientific Corporation (NYSE:BSX) SVP Sells 7,900 Shares of Stock
www.americanbankingnews.com - August 4 at 8:40 PM |
| Wendy Carruthers Sells 12,433 Shares of Boston Scientific Corporation (BSX) Stock
www.americanbankingnews.com - August 4 at 8:22 PM |
 | Boston Scientific’s Distribution Option Lapses
www.nasdaq.com - August 3 at 11:19 PM |
 | 10-Q: BOSTON SCIENTIFIC CORP
www.marketwatch.com - August 3 at 6:14 PM |
| Insider Selling: Boston Scientific Corporation (BSX) EVP Sells 10,000 Shares of Stock
www.americanbankingnews.com - August 2 at 8:34 PM |
| Equities Analysts Offer Predictions for Boston Scientific Corporation's Q2 2018 Earnings (NYSE:BSX)
www.americanbankingnews.com - August 2 at 3:28 PM |
| Boston Scientific Corporation (NYSE:BSX) Receives Buy Rating from UBS AG
www.americanbankingnews.com - August 1 at 10:28 PM |
| Boston Scientific Corporation (BSX) SVP Sells $57,015.00 in Stock
www.americanbankingnews.com - August 1 at 8:20 PM |
| Michael P. Phalen Sells 15,500 Shares of Boston Scientific Corporation (NYSE:BSX) Stock
www.americanbankingnews.com - August 1 at 7:48 PM |
| FY2017 EPS Estimates for Boston Scientific Corporation (NYSE:BSX) Lifted by SunTrust Banks
www.americanbankingnews.com - August 1 at 9:22 AM |
| Relative Strength Alert For Boston Scientific Corp.
www.nasdaq.com - July 31 at 9:51 PM |
| Boston Scientific To Participate In 2017 Canaccord Genuity Growth Conference
finance.yahoo.com - July 31 at 4:49 PM |
| Brokers Set Expectations for Boston Scientific Corporation's FY2017 Earnings (NYSE:BSX)
www.americanbankingnews.com - July 31 at 8:15 AM |
| Q3 2017 EPS Estimates for Boston Scientific Corporation Reduced by Analyst (NYSE:BSX)
www.americanbankingnews.com - July 31 at 7:51 AM |
| Leerink Swann Weighs in on Boston Scientific Corporation's Q3 2017 Earnings (BSX)
www.americanbankingnews.com - July 31 at 7:51 AM |
| Boston Scientific Corporation (BSX) Given a $29.00 Price Target at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - July 30 at 11:35 PM |
| Boston Scientific Corporation's (NYSE:BSX) Buy Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - July 30 at 3:56 PM |
| Boston Scientific Corporation 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - July 28 at 6:17 PM |
| Boston Scientific Announces Results for Second Quarter 2017
finance.yahoo.com - July 28 at 6:17 PM |
| Boston Scientific posts profit in second quarter
finance.yahoo.com - July 28 at 6:17 PM |
| Boston Scientific (BSX) Exceeds Q2 Earnings, Sales Estimates
finance.yahoo.com - July 28 at 6:17 PM |
| Boston Scientific Corp. breached its 50 day moving average in a Bearish Manner : BSX-US : July 27, 2017
finance.yahoo.com - July 28 at 6:16 PM |
| Edited Transcript of BSX earnings conference call or presentation 27-Jul-17 12:00pm GMT
finance.yahoo.com - July 28 at 6:16 PM |
| Boston Scientific Corporation (NYSE:BSX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 28 at 12:55 PM |
| Boston Scientific Corp Q2 Income Advances 19% - Nasdaq
www.nasdaq.com - July 27 at 5:19 PM |
| Earnings Reaction History: Boston Scientific Corporation, 37.5 ... - Nasdaq
www.nasdaq.com - July 27 at 5:19 PM |
| Boston Scientific tops Street 2Q forecasts
finance.yahoo.com - July 27 at 5:19 PM |
| Boston Scientific Corporation (NYSE:BSX) Releases Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - July 27 at 4:59 PM |
| Analysts Expect Boston Scientific Corporation (NYSE:BSX) Will Post Quarterly Sales of $2.21 Billion
www.americanbankingnews.com - July 27 at 11:22 AM |
| Boston Scientific Corporation (NYSE:BSX) Issues Q3 Earnings Guidance
www.americanbankingnews.com - July 27 at 11:13 AM |
| Boston Scientific Corporation (BSX) Updates FY17 Earnings Guidance
www.americanbankingnews.com - July 27 at 11:12 AM |
 | Breakfast Technical Briefing on Medical Equipment Stocks -- Abbott ... - PR Newswire (press release)
www.prnewswire.com - July 26 at 5:22 PM |
| Zacks: Brokerages Anticipate Boston Scientific Corporation (NYSE:BSX) to Announce $0.31 EPS
www.americanbankingnews.com - July 26 at 12:28 AM |
| Boston Scientific (BSX) Q2 Earnings: What Awaits the Stock? - Nasdaq
www.nasdaq.com - July 21 at 11:29 PM |
 | Boston Scientific joins in $36M round for Twin Cities med-tech startup
www.bizjournals.com - July 21 at 6:21 PM |
| Boston Scientific (BSX) Q2 Earnings: What Awaits the Stock?
finance.yahoo.com - July 21 at 6:21 PM |
| Abbott profit forecast gets a lift from St. Jude integration - Reuters
www.reuters.com - July 20 at 6:28 PM |
| Boston Scientific Corporation (BSX) Set to Announce Earnings on Thursday
www.americanbankingnews.com - July 20 at 7:40 AM |
| AxoGen, Inc. Appoints Jon Gingrich Chief Commercial Officer
feeds.benzinga.com - July 17 at 7:31 AM |
Boston Scientific Corporation (BSX) Chart for Saturday, August, 19, 2017
